Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Growth Rate of the Myeloproliferative Disorders Drugs Market?
The market for drugs treating myeloproliferative disorders has witnessed consistent growth in recent times. The market which was priced at $9.47 billion in 2024 is projected to be worth $9.92 billion in 2025 with a compound annual growth rate (CAGR) of 4.8%. Multiple factors have contributed to this growth during the historic period, including a rise in the number of myeloproliferative disorder cases, advancements in the comprehension of disease mechanisms, progress in clinical studies and drug development, enhanced diagnostic and screening methods, and heightened awareness and advocacy among patients.
What Growth Rate Is Forecasted for the Myeloproliferative Disorders Drugs Market by 2029?
The market for drugs targeted at myeloproliferative disorders is expected to witness stable growth in the coming years, eventually reaching $11.73 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 4.3%. This forecasted growth is owing to factors such as the growing elderly population, the rise in precision medicine, the introduction of innovative therapies, global attention to rare diseases as well as government actions and healthcare regulations. Key trends to note for the forecast period are the application of precision medicine, clinical trials of new therapies, better management of symptoms, increased utilisation of ruxolitinib, and a focus on identifying disease biomarkers.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10681&type=smp
Which Key Companies Are Shaping the Future of the Myeloproliferative Disorders Drugs Market?
Major companies operating in the myeloproliferative disorders drugs market include Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Incyte Corporation, Eli Lilly and Co, F Hoffmann-La Roche Ltd., Mylan NV, Fresenius Kabi AG, Hikma Pharmaceuticals plc, GSK plc, Bayer AG, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim International Gmbh, Sanofi Aventis Inc., AstraZeneca AB, Apotex Inc, Celgene Co., Gamida Cell Ltd., Geron Co., Promedior Inc., Johnson & Johnson Private Limited, AbbVie Inc., AOP Orphan Pharmaceuticals AG, Astellas Pharma Inc., Biogen Inc., Daiichi Sankyo Chemical Pharma Co. Ltd., Eisai Pharmaceuticals India Pvt. Ltd.
Which Factors Are Driving Demand in the Myeloproliferative Disorders Drugs Industry?
The increase in cases of myeloproliferative disorders is predicted to drive the advancement of the market for drugs targeting these conditions. Myeloproliferative disorders are a varied group of diseases characterized by the expansion of hematologic cell lines in the peripheral blood, separate from acute leukemia. The upsurge in these disorders is mostly attributed to genetic diseases, overexposure to chemicals, radiation, and electrical wiring, coupled with the elderly age group. Drugs for myeloproliferative diseases function by suppressing the BCR-ABL protein through binding to the ATP pocket in the active site, thereby halting downstream phosphorylation of the target protein, which aids in treating the disorder. For example, in August 2022, the National Institute of Health, a US-based medical research organization, reported that in 2022, chronic myelogenous leukemia had a higher prevalence in men, with about 2.4 new cases per 100,000, in comparison to 1.4 new cases per 100,000 in women. This fact shows an increase from 1.7 new cases in men and women per 100,000 each year in 2020. Consequently, the upsurge in myeloproliferative disorders cases is propelling the expansion of the drug market for these conditions.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=10681&type=smp
How Is the Myeloproliferative Disorders Drugs Market Segmented by Several Divisions?
The myeloproliferative disorders drugs market covered in this report is segmented –
1) By Type: Primary Myelofibrosis, Polycythemia Vera (PV), Essential Thrombocythemia (ET), Chronic Eosinophilic Leukemia Or Hyper eosinophilic Syndrome (HES), Systemic Masto cytosis (SM)
2) By Drug Type: JAK2 Inhibitors, Anti-Neoplastics, Demethylation Agents, Imatinib Mesylate, Other Drug Types
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Stores, Drug Stores
Subsegments:
1) By Primary Myelofibrosis: JAK Inhibitors, Immunomodulatory Agents, Supportive Care
2) By Polycythemia Vera (PV): JAK Inhibitors, Hydroxyurea, Phlebotomy, Interferon-alpha
3) By Essential Thrombocythemia (ET): JAK Inhibitors, Hydroxyurea, Anagrelide, Interferon-alpha
4) By Chronic Eosinophilic Leukemia or Hyper Eosinophilic Syndrome (HES): Tyrosine Kinase Inhibitors, Corticosteroids, Interferon-alpha
5) By Systemic Mastocytosis (SM): Tyrosine Kinase Inhibitors, Corticosteroids, Antihistamines, Immunotherapy
What are the Emerging Market Trends Driving the Growth of the Myeloproliferative Disorders Drugs Industry?
One significant trend gaining traction in the market for myeloproliferative disorder drugs is product innovation. Key players in this market, like GSK PLC, are focusing their efforts on inventing new products to consolidate their market position. An example of this was seen in September 2023 when the UK-based pharma and biotech firm announced that the FDA had approved momelotinib for the treatment of primary myelofibrosis, an MPD type. This promising new medication has a unique mode of action that can obstruct three vital signaling pathways: ACVR1, JAK1, and JAK2. Potential benefits of JAK1 and JAK2 inhibition may include the relief of splenomegaly and constitutional symptoms. It can also lessen the amount of hepcidin in circulation, which usually increases in myelofibrosis and leads to anemia; this reduction is due to the direct inhibition of ACVR1.
Access The Full Report Here:
Which Regions Are Driving Growth in the Myeloproliferative Disorders Drugs Market?
North America was the largest region in the myeloproliferative disorder drugs market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global myeloproliferative disorder drugs market report during the forecast period. The regions covered in the myeloproliferative disorders drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10681
This Report Delivers Insight On:
1. How big is the myeloproliferative disorders drugs market, and how is it changing globally?
2. Who are the major companies in the myeloproliferative disorders drugs market, and how are they performing?
3. What are the key opportunities and risks in the myeloproliferative disorders drugs market right now?
4. Which products or customer segments are growing the most in the myeloproliferative disorders drugs market?
5. What factors are helping or slowing down the growth of the myeloproliferative disorders drugs market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
